UNRESECTABLE OR METASTATIC MELANOMA
Clinical trials for UNRESECTABLE OR METASTATIC MELANOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE OR METASTATIC MELANOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE OR METASTATIC MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced melanoma: experimental combo faces off against approved treatment
Disease control Recruiting nowThis study tests whether a new combination of drugs (fianlimab and cemiplimab) works better than an already approved treatment (Opdualag) for people with advanced melanoma that cannot be removed by surgery or has spread. About 560 adults with previously untreated melanoma will re…
Matched conditions: UNRESECTABLE OR METASTATIC MELANOMA
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy aims to tackle melanoma that resists treatment
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of two drugs, enfortumab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma that has worsened after standard therapy. The study will enroll 60 adults with unresectable stage III or IV melanoma. Researc…
Matched conditions: UNRESECTABLE OR METASTATIC MELANOMA
Phase: PHASE2 • Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Disease control
Last updated Jun 26, 2026 17:53 UTC
-
Melanoma drug duel: which combo boosts immunity more?
Knowledge-focused Recruiting nowThis study looks at how two different drug combinations affect the immune system in people with advanced melanoma that cannot be removed by surgery. Researchers will compare Opdualag (nivolumab/relatlimab) with cemiplimab/fianlimab by analyzing blood and tumor samples from 20 par…
Matched conditions: UNRESECTABLE OR METASTATIC MELANOMA
Sponsor: John Kirkwood • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC